RxDoctor Payments Data

Hannah Jaster, PA

Physician Assistant · Arlington, WANPI 1861157505

Payments from drug & device makers

$4,170in general payments, 2019–2025

Across 90 payments — averaging $46.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$1K
  • Relievant Medsystems, Inc.$1K
  • Collegium Pharmaceutical, Inc.$540
  • AbbVie$364
  • Boston Scientific$259
  • Biohaven Pharmaceutical Holding Company Ltd.$74
  • plus $272 from 8 others

What the payments were for

  • Travel & lodging$1,84844%
  • Food & beverage$2,32356%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,170 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$154,742
Medicare patients
184
Services billed
1,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl73$52,762
Xtampza ErOxycodone Myristate63$44,539
Buprenorphine130$30,943
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen911$25,018
Nucynta ErTapentadol Hcl14$17,420
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen499$15,092
Oxycodone Hcl669$12,342
Morphine Sulfate ErMorphine Sulfate333$8,230
Fentanyl94$7,403
OxycontinOxycodone Hcl11$4,063
Gabapentin197$3,192
Pregabalin116$2,658
Tizanidine Hcl176$2,376
Hydromorphone Hcl185$2,270
Tramadol Hcl ErTramadol Hcl54$2,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er$540$114,721150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Arlington

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →